drugset / Trial / NCT05127525

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525

Phase 3 Terminated 5 enrolled iRenix Medical, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 30 centers in the United States (US).

Timeline

Start
2021-11-15
Primary completion
2022-01-31
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IRX-101 Unknown Topical
Comparator Povidone-Iodine Other / unclassified Topical